Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PCOS mystery: could a pregnancy hormone be the key to inherited risk?

NCT ID NCT03483792

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 58 pregnant women with and without PCOS to understand how hormones like AMH and leptin might be passed to their babies. Researchers measured these hormones in the mother's blood during each trimester and in the placenta after birth. The goal was to see if higher AMH levels in pregnancy could explain why daughters of women with PCOS are more likely to develop the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help explain why daughters of women with PCOS have a higher risk of developing the condition, pointing toward potential early interventions.
What could go wrong
This is a small, observational study that only measures hormone levels during pregnancy. It does not test any treatment, so it cannot directly lead to a cure or therapy on its own.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

58 people

The number who actually took part.

Started

Apr 2018

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients having a pre-conceptionnal infertility assessment in the gynecology-Endocrinology department of the CHRU of Lille, in the first trimester of monofetal pregnancy (between 5 and 10 weeks of gestation), obtained spontaneously, after induction of ovulation or Assisted Reproductive Techniques (ART)

Ages

18 to 43 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Having a pre-conceptional infertility assessment in the gynecology-Endocrinology department of University Hospital of Lille * in the first trimester of mono fetal pregnancy (between 5 and 10 weeks of gestation), obtained spontaneously, after induction of ovulation or Assisted Reproductive Techniques (ART) * Pregnancy followed at University Hospital of Lille * PCOS group: defined according to modified Rotterdam criteria (2003 and 2011) * At least 2 of the following 3 criterion: * Cycle disorder * Clinical and / or biological hyperandrogenism * Ovarian volume \> 10cm³ and/or more than 19 follicles from 2 to 9 mm per ovary * After exclusion of other causes of cycle disorder or hyperandrogenism * Control group: patient with severe male and / or tubal infertility, no cycling disorder, normal ovarian reserve (FSH\<10 IU / L, E2\<50 pg / ml, AMH\>7 and \<35 pmol / L and Follicles count between \>5 and \<20 per ovary at day 3 of the cycle). In the group of female controls, the fertility problem is not related to a female pathology of the hypothalamic-pituitary-ovarian axis (tubal or male infertility). They are women without ovarian personal pathology. The problem of fertility being of other origin. Exclusion Criteria: * Multiple pregnancy * Pregnancy after egg donation * Long-term drug therapy (excluding routine pregnancy supplementation) * Previous Diabetes * Bariatric surgery * Patients with ovulatory infertility of central or idiopathic origin * Patients already included in another protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycystic ovary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycystic ovary syndrome

Contacts and locations

Locations

  • Hôpital Jeanne de Flandres, CHU

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.